🇺🇸 FDA
Patent

US 11590132

Pyruvate kinase activators for use in treating blood disorders

granted A61KA61K31/5025A61K31/506

Quick answer

US patent 11590132 (Pyruvate kinase activators for use in treating blood disorders) held by Agios Pharmaceuticals, Inc. expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Agios Pharmaceuticals, Inc.
Grant date
Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/5025, A61K31/506, A61K31/519, A61K45/06